$GHRS

Lynx1 Capital Management (NASDAQ: GHRS) reports 19.3% stake in GH Research

Lynx1 Capital Management LP and Weston Nichols reported beneficial ownership of GH Research PLC ordinary shares. Using 68,608,919 shares outstanding as of May 12, 2026, they collectively hold 13,263,288 shares, or 19.3% of the class, with shared voting and dispositive power, and rights to dividends and sale proceeds.

Original reporting
Published Aug 14, 2026, 8:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 6:49 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$GHRS
Neutral
medium confidence
Mentioned
$GHRS
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$GHRSNeutralLow
01

Why it matters

The key new information is the size of the stake (19.3%) and the share count (13,263,288) based on shares outstanding as of May 12, 2026. This can matter for governance expectations and potential strategic outcomes, but it does not provide operational or financial updates.

02

Market read

Traders may monitor for follow-on activism, board changes, or strategic transactions, but this specific article only provides ownership disclosure details.

03

What to watch

Shared voting and dispositive power (no sole power) can reduce the likelihood of immediate control-driven actions; the article also does not mention activist demands, board seats, or a timeline.

Relevance 4/10Novelty 4/10Timing: filing disclosed on 2026-08-14, useful for positioning ahead of any follow-on activism or governance moves

Background

The article summarizes a Schedule 13 beneficial ownership disclosure by Lynx1 Capital Management LP and Weston Nichols for GH Research PLC ordinary shares.

Company-level read

Ticker impact

$GHRSNeutralMedium confidence
Context

Lynx1 Capital Management disclosed a 19.3% beneficial stake in GH Research PLC, totaling 13,263,288 ordinary shares.

Expected impact

Near-term price reaction is likely limited unless follow-on actions (board changes, tender offer, or activism) are disclosed; otherwise expect sentiment-driven volatility.

Evidence & confidence

The article is a Schedule 13 disclosure of beneficial ownership (19.3%) with shared voting/dispositive power, which informs positioning but does not state new business developments.

Market effects

Limited sector read-through because the disclosure is company-specific ownership, not a sector-wide regulatory or demand signal.

Minimal, as the event is a US-listed ADR/US trading vehicle ownership disclosure tied to a specific issuer.

Low, unless the stake triggers cross-border governance or strategic actions that are not mentioned here.

Counterpoint

A disclosed 19.3% stake may be passive or hedged, with no intent to influence strategy, so the market may overreact to ownership alone.

Key entities

  • GH Research PLC

    Company subject of the beneficial ownership disclosure; Lynx1 reports 19.3% of the ordinary shares class.

  • Lynx1 Capital Management LP

    Reporting person disclosing beneficial ownership via Lynx1 Master Fund LP and a managed account.

  • Weston Nichols

    Co-reporting person associated with the disclosed beneficial ownership.

Related articles

$LLYMedAI 8/10

Why Psychedelic stocks are surging today By Investing.com

Investing.com reports that Eli Lilly agreed to acquire AtaiBeckley Inc. for $6.75 per share in cash plus up to $2.50 per share via a contingent value right tied to milestones. The deal values AtaiBeckley at about $2.8B equity plus about $1.0B potential CVR and is expected to close in Q3. AtaiBeckley shares rose 30.8% premarket; Compass Pathways and GH Research also gained. RBC reiterated an Outperform rating on GH Research with a $40 target.

$GHRSMed

Why is GH Research stock surging today? By Investing.com

GH Research PLC shares rose about 16% in pre-open after Bloomberg reported Eli Lilly is in advanced talks to acquire AtaiBeckley, a developer targeting treatment-resistant depression. The news could be announced within a week. RBC Capital Markets cited GH Research as the strongest read-through to the deal, and the stock traded above its prior 52-week high.

$GHRSMedAI 9/10

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GH Research PLC (Nasdaq: GHRS) said it has published full Phase 2a results for inhaled mebufotenin (GH001) in postpartum depression in The Journal of Clinical Psychiatry. The single-arm open-label trial enrolled 10 adult women; mean MADRS fell 35.4 points to Day 8, 10/10 remitted within 2 hours, and no serious adverse events were reported. Two Phase 2b TRD-201 data oral presentations were accepted for CINP 2026.